​
​

PolyPid Stock (NASDAQ:PYPD)

ForecastOwnershipFinancialsChartTranscripts
PolyPid by TradingView

Previous Close

$3.36

52W Range

$2.95 - $9.20

50D Avg

$3.47

200D Avg

$4.41

Market Cap

$22.66M

Avg Vol (3M)

$5.42K

Beta

1.32

Div Yield

-

PYPD Company Profile

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

59

IPO Date

Jun 26, 2020

Website

PYPD Performance

PYPD Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-22.87M$-38.89M$-42.88M
Net Income$-23.86M$-39.52M$-40.71M
EBITDA$-22.87M$-38.89M$-42.88M
Basic EPS$-16.79$-55.16$-65.12
Diluted EPS$-16.79$-55.16$-65.12

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 24Aug 14, 24 | 1:25 PM
Q1 24May 08, 24 | 12:00 AM
Q4 23Feb 14, 24 | 11:13 AM

Peer Comparison

TickerCompany
CUECue Biopharma, Inc.
BWVOnconetix, Inc.
VRPXVirpax Pharmaceuticals, Inc.
KPRXKiora Pharmaceuticals, Inc.
REVBRevelation Biosciences, Inc.
LABPLandos Biopharma, Inc.
HILSTharimmune, Inc.
VACCBarinthus Biotherapeutics plc
VRAXVirax Biolabs Group Limited
EFTReFFECTOR Therapeutics, Inc.
INABIN8bio, Inc.
CYTOAltamira Therapeutics Ltd.
ANEBAnebulo Pharmaceuticals, Inc.
PYXSPyxis Oncology, Inc.
ANIXAnixa Biosciences, Inc.
INMBINmune Bio, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.